KCNK16
ENSG00000095981
Chromosome
6
- Chemical probe available
- No
- Target name
- KCNK16
- Gene name
- Potassium two pore domain channel subfamily K member 16
- Gene symbol
- KCNK16
- Protein name
- Potassium channel subfamily K member 16 (2P domain potassium channel Talk-1) (TWIK-related alkaline pH-activated K(+) channel 1) (TALK-1)
- K2p16.1
- TALK-1
- TALK1
- Gene biotype
- Protein coding
- Gene family
- Potassium two pore domain channel subfamily K
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 2.51
- Tissue specificity (Gini)
- 0.948
- Tissue specificity (tau)
- 0.993
- KEGG gene identifiers
- hsa:83795
- Protein interaction confidence
- 0.74
- Protein interaction partners
- 2
- R-HSA-1299361
- R-HSA-5576886
- End position
- 39322968
- Start position
- 39314698
- Chromosome
- 6
- Strand
- Reverse
- [Isoform a]: Endoplasmic reticulum membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein .
- SUBCELLULAR LOCATION: [Isoform b]: Endoplasmic reticulum membrane
- Multi-pass membrane protein . Mitochondrion inner membrane
- Multi-pass membrane protein .
- PubMed 28928238
- PubMed 26239056
- PubMed 38206814
- Tissue specificity (tau)
- 0.993009
- Expression inequality (Gini)
- 0.948428
Expression in transcripts per million
- Pancreas
- 2.51
- Stomach
- 0.27
- Thyroid
- 0.22
- Testis
- 0.16
- Artery - Aorta
- 0.07
Expression in transcripts per million
- Pancreas2.51
- Stomach0.27
- Thyroid0.22
- Testis0.16
- Artery - Aorta0.07
- Lung0.05
- Pituitary0.03
- Brain - Spinal cord (cervical c-1)0.03
- Artery - Coronary0.03
- Small Intestine - Terminal Ileum0.02
- Brain - Substantia nigra0.02
- Brain - Hippocampus0.02
- Brain - Putamen (basal ganglia)0.01
- Muscle - Skeletal0
- Cells - Cultured fibroblasts0
- Adrenal Gland0
- Whole Blood0
- Kidney - Medulla0
- Artery - Tibial0
- Uterus0
- Ovary0
- Cells - EBV-transformed lymphocytes0
- Brain - Cortex0
- Skin - Sun Exposed (Lower leg)0
- Brain - Anterior cingulate cortex (BA24)0
And 29 more, listed on the interactive page.
- GO:0006813
- GO:0032469
- GO:0051279
- GO:0098900
- GO:0005789
- GO:0005886
- GO:0005267
- GO:0005515
- GO:0015271
- GO:0042802
- GO:0046982
Related records
Trials (123)
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- A Phase 1 Study Comparing AVP-786 With AVP-923
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
- A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous Propofol
- A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
- A Study to Evaluate the Effect of Genotype on LY2216684
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
- AnaConDa Long Term Sedation Study
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
- Automated Control of End-tidal Volatile Anesthetic Concentration
- Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
Drugs (3)
- Chloroform
- Isoflurane
- Quinidine